LENZ
LENZ Therapeutics, Inc.
Price Chart
Latest Quote
$5.27
-0.30 (-5.39%)
Current Price
| Previous Close | $5.57 |
| Open | $5.63 |
| Day High | $5.72 |
| Day Low | $5.27 |
| Volume | 344,738 |
Stock Information
| Shares Outstanding | 31.35M |
| Total Debt | $673K |
| Cash Equivalents | $258.38M |
| Revenue | $20.99M |
| Net Income | $-109.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $165.24M |
| EPS (TTM) | $-3.64 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-82.75M |
| Sales | $20.99M |
| Income | $-109.00M |
| Book/sh | $7.86 |
| Cash/sh | $8.24 |
| Employees | 152 |
Financial Ratios
| Quick Ratio | 10.11 |
| Current Ratio | 10.40 |
| Debt/Eq | 0.27 |
Returns & Margins
| ROA | -31.22% |
| ROE | -49.71% |
| Gross Margin | 92.88% |
| Operating Margin | -2321.67% |
Ownership
| Insider Ownership | 2.65% |
| Institutional Ownership | 107.63% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.52 |
| P/S | 7.87 |
| P/B | 0.67 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $32.00 |
Technical Indicators
| SMA20 | $6.65 |
| SMA50 | $7.93 |
| SMA200 | $19.36 |
| RSI | 13.03 |
| ATR | 0.4435 |
| Shares Float | 18.47M |
| Short Float | 53.75% |
| Short Ratio | 11.29 |
| Volatility | 1.47 |
| Rel Volume | 0.54 |
Performance History
| Week | -16.88% |
| Month | -32.00% |
| Quarter | -41.90% |
| 6 Months | -70.09% |
| YTD | -67.06% |
| Year | -82.30% |
| 3 Years | -45.08% |
| 10 Years | -91.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $5.27 | 344,738 |
| 2026-06-24 | $5.58 | 772,800 |
| 2026-06-23 | $5.75 | 727,500 |
| 2026-06-22 | $5.82 | 1,333,900 |
| 2026-06-18 | $6.15 | 1,125,200 |
| 2026-06-17 | $6.34 | 688,900 |
| 2026-06-16 | $6.52 | 239,600 |
| 2026-06-15 | $6.63 | 465,800 |
| 2026-06-12 | $6.77 | 283,600 |
| 2026-06-11 | $6.50 | 973,000 |
| 2026-06-10 | $6.58 | 338,500 |
| 2026-06-09 | $6.79 | 374,600 |
| 2026-06-08 | $6.72 | 303,300 |
| 2026-06-05 | $7.01 | 494,600 |
| 2026-06-04 | $7.20 | 367,900 |
| 2026-06-03 | $7.01 | 511,300 |
| 2026-06-02 | $7.13 | 628,200 |
| 2026-06-01 | $7.44 | 976,900 |
| 2026-05-29 | $7.78 | 1,017,500 |
| 2026-05-28 | $7.99 | 717,800 |
| 2026-05-27 | $7.73 | 1,002,100 |
| 2026-05-26 | $7.75 | 709,800 |
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
đ° Latest News
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
Proactive âĸ 2026-06-08T15:33:00Z
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade
Simply Wall St. âĸ 2026-05-16T14:12:50Z
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St. âĸ 2026-05-14T13:16:18Z
Top Midday Decliners
MT Newswires âĸ 2026-05-12T17:59:06ZToast downgraded, Lowe's upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-12T13:56:25Z
Here Are Tuesdayâs Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Loweâs, Matador Resources, Toast and More
24/7 Wall St. âĸ 2026-05-12T11:54:21Z
LENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...
GuruFocus.com âĸ 2026-05-12T07:07:00ZLENZ Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-12T01:06:53Z
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-11T21:25:02Z
President of LENZ Therapeutics Picks Up 57% More Stock
Simply Wall St. âĸ 2026-04-01T10:20:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $418,000 | $0 | - | - |
| Cost Of Revenue | $418,000 | $0 | - | - |
| Total Revenue | $19,088,000 | $0 | $0 | $15,000,000 |
| Operating Revenue | $19,088,000 | $0 | $0 | $15,000,000 |
| Expenses | ||||
| Total Expenses | $110,226,000 | $58,610,000 | $72,429,000 | $25,483,000 |
| Other Income Expense | $-243,000 | $289,000 | $93,000 | $19,000 |
| Other Non Operating Income Expenses | $-243,000 | $289,000 | $93,000 | $19,000 |
| Net Non Operating Interest Income Expense | $9,756,000 | $8,553,000 | $2,189,000 | - |
| Operating Expense | $109,808,000 | $58,610,000 | $72,429,000 | $25,483,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Net Interest Income | $9,756,000 | $8,553,000 | $2,189,000 | - |
| Interest Income | $9,756,000 | $8,553,000 | $2,189,000 | - |
| Normalized Income | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Net Income From Continuing And Discontinued Operation | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Total Operating Income As Reported | $-91,138,000 | $-58,610,000 | $-72,429,000 | $-10,483,000 |
| Net Income Common Stockholders | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Net Income | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Net Income Including Noncontrolling Interests | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Net Income Continuous Operations | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Pretax Income | $-81,625,000 | $-49,768,000 | $-70,147,000 | $-10,464,000 |
| Interest Income Non Operating | $9,756,000 | $8,553,000 | $2,189,000 | - |
| Operating Income | $-91,138,000 | $-58,610,000 | $-72,429,000 | $-10,483,000 |
| Gross Profit | $18,670,000 | $0 | - | - |
| Per Share | ||||
| Diluted EPS | $-2.85 | $-2.34 | $-2.74 | $-0.42 |
| Basic EPS | $-2.85 | $-2.34 | $-2.74 | $-0.42 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-90,851,000 | $-58,552,000 | $-72,414,000 | $-10,475,000 |
| Reconciled Depreciation | $287,000 | $58,000 | $15,000 | $8,000 |
| EBITDA (Bullshit earnings) | $-90,851,000 | $-58,552,000 | $-72,414,000 | $-10,475,000 |
| EBIT | $-91,138,000 | $-58,610,000 | $-72,429,000 | $-10,483,000 |
| Diluted Average Shares | $28,813,164 | $21,281,038 | $25,533,533 | $25,533,533 |
| Basic Average Shares | $28,813,164 | $21,281,038 | $25,533,533 | $25,533,533 |
| Diluted NI Availto Com Stockholders | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Tax Provision | $502,000 | $1,000 | $-179,000 | $347,000 |
| Research And Development | $18,670,000 | $29,801,000 | $59,504,000 | $21,125,000 |
| Selling General And Administration | $91,138,000 | $28,809,000 | $12,925,000 | $4,358,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Total Assets | $305,876,000 | $215,304,000 | $70,376,000 | $46,951,000 |
| Total Non Current Assets | $4,464,000 | $3,387,000 | $3,132,000 | $310,000 |
| Other Non Current Assets | $2,541,000 | $1,398,000 | - | - |
| Current Assets | $301,412,000 | $211,917,000 | $67,244,000 | $46,641,000 |
| Other Current Assets | $5,800,000 | $2,773,000 | $1,450,000 | $2,200,000 |
| Restricted Cash | $0 | $114,000 | $0 | - |
| Inventory | $2,936,000 | $0 | - | - |
| Receivables | $329,000 | $0 | - | - |
| Accounts Receivable | $329,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $292,347,000 | $209,030,000 | $65,794,000 | $44,441,000 |
| Cash And Cash Equivalents | $25,179,000 | $20,158,000 | $35,140,000 | $44,441,000 |
| Non Current Prepaid Assets | - | $1,398,000 | $21,000 | $31,000 |
| Non Current Deferred Assets | - | $0 | $2,739,000 | - |
| Cash Financial | - | - | - | $44,441,000 |
| Debt | ||||
| Total Debt | $815,000 | $1,381,000 | $329,000 | $250,000 |
| Long Term Debt And Capital Lease Obligation | $350,000 | $814,000 | $192,000 | $147,000 |
| Current Debt And Capital Lease Obligation | $465,000 | $567,000 | $137,000 | $103,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,537,000 | $11,220,000 | $163,088,000 | $71,120,000 |
| Total Non Current Liabilities Net Minority Interest | $350,000 | $814,000 | $144,574,000 | $61,621,000 |
| Current Liabilities | $21,187,000 | $10,406,000 | $18,514,000 | $9,499,000 |
| Payables And Accrued Expenses | $20,722,000 | $9,839,000 | $18,377,000 | $9,396,000 |
| Payables | $4,167,000 | $4,257,000 | $5,711,000 | $5,102,000 |
| Accounts Payable | $4,167,000 | $4,257,000 | $5,711,000 | $4,755,000 |
| Derivative Product Liabilities | - | $0 | $871,000 | $994,000 |
| Other Non Current Liabilities | - | - | $121,000 | $66,000 |
| Total Tax Payable | - | - | - | $347,000 |
| Income Tax Payable | - | - | - | $347,000 |
| Equity | ||||
| Common Stock Equity | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Total Equity Gross Minority Interest | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Stockholders Equity | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Gains Losses Not Affecting Retained Earnings | $242,000 | $196,000 | $6,000 | - |
| Other Equity Adjustments | $242,000 | $196,000 | $6,000 | - |
| Retained Earnings | $-227,141,000 | $-145,014,000 | $-95,245,000 | $-25,277,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $143,390,000 | $60,414,000 |
| Other | ||||
| Ordinary Shares Number | $31,344,782 | $27,518,439 | $25,533,533 | $25,533,533 |
| Share Issued | $31,344,782 | $27,531,490 | $25,533,533 | $25,533,533 |
| Tangible Book Value | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Invested Capital | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Working Capital | $280,225,000 | $201,511,000 | $48,730,000 | $37,142,000 |
| Capital Lease Obligations | $815,000 | $1,381,000 | $329,000 | $250,000 |
| Total Capitalization | $284,339,000 | $204,084,000 | $-92,712,000 | $-24,169,000 |
| Additional Paid In Capital | $511,237,000 | $348,901,000 | $2,517,000 | $1,098,000 |
| Capital Stock | $1,000 | $1,000 | $10,000 | $10,000 |
| Common Stock | $1,000 | $1,000 | $10,000 | $10,000 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $350,000 | $814,000 | $192,000 | $147,000 |
| Current Capital Lease Obligation | $465,000 | $567,000 | $137,000 | $103,000 |
| Current Accrued Expenses | $16,555,000 | $5,582,000 | $12,666,000 | $4,294,000 |
| Net PPE | $1,923,000 | $1,989,000 | $372,000 | $279,000 |
| Accumulated Depreciation | $-355,000 | $-68,000 | $-27,000 | $-12,000 |
| Gross PPE | $2,278,000 | $2,057,000 | $399,000 | $291,000 |
| Leases | $108,000 | $100,000 | $12,000 | - |
| Other Properties | $734,000 | $1,338,000 | $318,000 | $245,000 |
| Machinery Furniture Equipment | $1,436,000 | $619,000 | $69,000 | $46,000 |
| Properties | $0 | $0 | $0 | - |
| Finished Goods | $175,000 | - | - | - |
| Raw Materials | $2,761,000 | - | - | - |
| Other Short Term Investments | $267,168,000 | $188,872,000 | $30,654,000 | - |
| Treasury Shares Number | - | $13,051 | - | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-69,997,000 | $-59,859,000 | $-60,410,000 | $-4,128,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-69,170,000 | $-59,391,000 | $-60,380,000 | $-4,091,000 |
| Cash Flow From Continuing Operating Activities | $-69,170,000 | $-59,391,000 | $-60,380,000 | $-4,091,000 |
| Operating Gains Losses | - | $1,063,000 | $-123,000 | $-21,000 |
| Investing Activities | ||||
| Capital Expenditure | $-827,000 | $-468,000 | $-30,000 | $-37,000 |
| Investing Cash Flow | $-75,668,000 | $-154,479,000 | $-29,621,000 | $-37,000 |
| Cash Flow From Continuing Investing Activities | $-75,668,000 | $-154,479,000 | $-29,621,000 | $-37,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $147,749,000 | $79,513,000 | $82,976,000 | $30,133,000 |
| Financing Cash Flow | $149,745,000 | $199,002,000 | $80,700,000 | $30,262,000 |
| Cash Flow From Continuing Financing Activities | $149,745,000 | $199,002,000 | $80,700,000 | $30,262,000 |
| Net Common Stock Issuance | $147,749,000 | $79,513,000 | $0 | - |
| Common Stock Issuance | $147,749,000 | $79,513,000 | $0 | - |
| Net Other Financing Charges | - | $115,451,000 | $-2,479,000 | - |
| Net Preferred Stock Issuance | - | $0 | $82,976,000 | $30,133,000 |
| Preferred Stock Issuance | - | $0 | $82,976,000 | $30,133,000 |
| Other | ||||
| End Cash Position | $25,179,000 | $20,272,000 | $35,140,000 | $44,441,000 |
| Beginning Cash Position | $20,272,000 | $35,140,000 | $44,441,000 | $18,307,000 |
| Changes In Cash | $4,907,000 | $-14,868,000 | $-9,301,000 | $26,134,000 |
| Proceeds From Stock Option Exercised | $1,996,000 | $4,038,000 | $203,000 | $129,000 |
| Net Investment Purchase And Sale | $-74,841,000 | $-154,011,000 | $-29,591,000 | - |
| Sale Of Investment | $205,962,000 | $87,900,000 | $22,500,000 | - |
| Purchase Of Investment | $-280,803,000 | $-241,911,000 | $-52,091,000 | - |
| Net PPE Purchase And Sale | $-827,000 | $-468,000 | $-30,000 | $-37,000 |
| Purchase Of PPE | $-827,000 | $-468,000 | $-30,000 | $-37,000 |
| Change In Working Capital | $3,450,000 | $-13,091,000 | $9,410,000 | $6,012,000 |
| Change In Other Current Assets | $196,000 | $-1,377,000 | $10,000 | $-29,000 |
| Change In Payables And Accrued Expense | $10,885,000 | $-11,739,000 | $8,639,000 | $8,153,000 |
| Change In Accrued Expense | $10,975,000 | $-7,460,000 | $7,783,000 | $3,858,000 |
| Change In Payable | $-90,000 | $-4,279,000 | $856,000 | $4,295,000 |
| Change In Account Payable | $-90,000 | $-4,279,000 | $856,000 | $4,295,000 |
| Change In Prepaid Assets | $-3,027,000 | $25,000 | $761,000 | $-2,112,000 |
| Change In Inventory | $-4,275,000 | $0 | - | - |
| Change In Receivables | $-329,000 | $0 | - | - |
| Changes In Account Receivables | $-329,000 | $0 | - | - |
| Stock Based Compensation | $12,547,000 | $6,365,000 | $1,343,000 | $721,000 |
| Asset Impairment Charge | $82,000 | $0 | - | - |
| Amortization Of Securities | $-3,409,000 | $-4,017,000 | $-1,057,000 | - |
| Depreciation Amortization Depletion | $287,000 | $58,000 | $15,000 | $8,000 |
| Depreciation And Amortization | $287,000 | $58,000 | $15,000 | $8,000 |
| Gain Loss On Sale Of PPE | $0 | $16,000 | $0 | - |
| Net Income From Continuing Operations | $-82,127,000 | $-49,769,000 | $-69,968,000 | $-10,811,000 |
| Gain Loss On Investment Securities | - | $1,047,000 | $-123,000 | $-21,000 |
Fetched: 2026-06-25